Federated Hermes, Inc. Theravance Biopharma, Inc. Transaction History

Federated Hermes, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$14.89 - $20.16 $804 - $1,088	-54 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$14.79 - $22.49 $4.51 Million - $6.86 Million	-305,116 Reduced 99.98%	54 $1,000
Q2 2020 Aug 13, 2020	SELL	$20.64 - $30.69 $1.98 Million - $2.94 Million	-95,804 Reduced 23.89%	305,170 $6.41 Million
Q1 2020 May 13, 2020	BUY	$17.84 - $31.21 $7.15 Million - $12.5 Million	400,970 Added 0.0%	400,974 $9.27 Million
Q4 2019 Feb 14, 2020	SELL	$16.12 - $25.89 $290 - $466	-18 Reduced 81.82%	4 $1,000
Q3 2019 Nov 14, 2019	BUY	$16.51 - $23.78 $363 - $523	22 New	22 $1,000
Q2 2019 Aug 14, 2019	SELL	$15.6 - $25.15 $717,724 - $1.16 Million	-46,008 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$22.52 - $35.07 $1.04 Million - $1.61 Million	46,008 New	46,008 $1.18 Million

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.